Past events

To support the APAC geographic expansion strategy, we are excited to announce our upcoming APAC Virtual Summit. This summit will provide insights into CGT development, regulations, and commercialization in APAC. Participants will gain access to presentations, in-depth discussions and expert-led panels covering strategies innovative development, regulatory framework and commercialization.

The 15th Biosimilars and Biologics Global Congress 2025 will offer a valuable opportunity for knowledge acquisition, professional networking, and collaborative solutions. We will explore vital topics such as improving patient access to biotherapies, encouraging robust market competition, understanding the newest developments in regulatory science, and examining the transformative impact of biosimilar medicines on healthcare systems and the supporting industrial landscape.

Since its inception in 2010 the Health Datapalooza has served as a vital forum for public-private collaboration on data-driven health care innovation. Hosted by AcademyHealth, the 2025 Health Datapalooza will bring together stakeholders from across the health care ecosystem to examine the evidence, assess the value, and discuss the real-world application of innovative solutions transforming health care.

This event serves as an important platform to showcase major therapeutic advances which may enter Australia’s regulatory or reimbursement systems within the decade and may represent a significant disruption in the treatment paradigm and/or require innovation in health care system planning. The Forum also highlights the potential implications for governments from the introduction of these advances in terms of resources, systems and processes. 

Real-world evidence is becoming an indispensable tool for pharma companies. The availability of digital health tools, electronic health records and advances in data analytics have facilitated the large-scale collection of real-world data, enabling a wealth of insights into patient outcomes and clinical effectiveness and safety of medicines beyond clinical trials. This Financial Times webinar will bring together global biopharma companies, health regulators, health technology assessors, and other industry experts to explore the evolving landscape for real-world evidence (RWE) in Europe, and how the regional and global evidence base can be improved and harmonised to revolutionise healthcare decision-making, drug development and patient care.

This one-day programme empowers Commercial and Medical Affairs managers to become highly effective contributors to the cross-functional process required for a successful omnichannel pharma brand launch.

This technical workshop is specifically designed for people working within pharmaceutical companies who are responsible for preparing NICE technology appraisal or highly specialised technology appraisal submissions and supporting consultancies

In this course you will get many tips and tricks on how to choose the most effective tactics to reach the goals set in the Medical Plan, and on how to optimally plan and execute them throughout the year. Participate in this course for the unique opportunity to gain advice for your specific questions from a true Medical Affairs expert. Join a group of your international cross-industry peers, mostly medical advisors and medical science liaisons, to learn from their experiences, discuss common issues and gain new ideas.

By attending this 2-day course you will quickly get up the learning curve and know how to apply AI most effectively and efficiently in your pharma marketing role. You will not only have the chance to ask your specific questions to a true AI-Pharma Marketing expert, but also benefit from the unique opportunity to share experiences and engage in in-depth discussions with your international peers.

This introductory course is designed to teach academic researchers, health policy decision makers, manufacturers, and clinicians about the key elements, methods, and language of health technology assessment (HTA). The course provides an overview of basic HTA principles including benefit assessment (biostatistics, clinical epidemiology, patient-relevant outcomes, risk-benefit assessment), economic evaluation (costing, cost-effectiveness analysis, pharmacoeconomic modeling, budget impact analysis, resource allocation), and ELSI (ethical, legal, and social implications).

This course will equip you with the knowledge and tools to engage effectively with the right key opinion leaders at the right time in a product’s lifecycle, ensuring the strategic needs of your products are met, as set out in the Medical/Brand Plan.

The goal of this course is to equip senior biotech and pharma executives with best practices to prepare for and execute every step of the process. You will acquire the most critical out-licensing skills, concepts, and tools. By participating, you will not only have the chance to ask your specific questions of a true expert, but also experience the unique opportunity to share experiences and engage in in-depth discussions with your international peers.

Most countries have their own Health Technology Assessment (HTA) body with specific views about which criteria to be used and how the HTA process should be conducted. On top of that, EU-level networks strive for a more efficient use of resources and increased collaboration between all stakeholders involved. In this 1-day course you will learn how companies should optimise processes and criteria in this complex environment.

For many pharma companies, the most significant source of new products lies in Business Development. Often, the business development function falls short due to a lack of strategic alignment and a failure to coordinate efforts across the organisation. To optimise successful transactions and partnerships, companies need a structured business development and licensing process, and all contributors need to understand the whole process. This course offers a unique opportunity to speed up your learning curve by giving you a comprehensive overview of the licensing process in the context of business development in the pharma-biotech world.

This two day course is your fast track to mastering the current use of the most powerful AI tools in market access. You'll gain practical insights and expert advice on applying AI effectively and confidently in your market access role.

This course, led by two of Europe’s most respected forecasting experts in pharma, will teach you the evidence-based concepts, models and techniques that work best to forecast the sales of pharmaceuticals.

This course is a must for brand/product managers and related pharma marketers early in their career because they need to quickly acquire the concepts and tools for generating successful brand marketing plans, as well as think and learn to act cross-functionally in today’s volatile, uncertain and complex environment. This course will also benefit more experienced brand managers and franchise leads who want to refresh their skills, as well as managers in medical affairs, market access and commercial functions who must contribute to agile and customer-centric brand planning processes.

Uniting 70+ leaders across Pricing & Reimbursement, Market Access, Marketing Commercial, Government Affairs, Policy, Real-World Evidence, and HEOR domains, this year’s summit provided actional insights for all attendees, whether they were looking to establish a market access department, launch successfully, or bolster the commercial performance of in-market therapies.

This course, led by two of Europe’s most respected forecasting experts in pharma, will teach you the evidence-based concepts, models and techniques that work best to forecast the sales of pharmaceuticals.

The Evidence 360: RWE, Pricing & Reimbursement Summit Europe focuses on the impact of Real World Evidence (RWE), pricing models, and reimbursement strategies in healthcare, addressing challenges like data analytics, regulatory issues, and personalized medicine in Europe.